{
  "nctId": "NCT05246228",
  "briefTitle": "Immune System Modulation and Outcome in High-risk cSCC Treated With Surgery and Radiotherapy",
  "officialTitle": "Immune System Modulation and Outcome in High-risk Cutaneous Squamous Cell Carcinoma Treated With Surgery and Radiotherapy: a Prospective Study",
  "protocolDocument": {
    "nctId": "NCT05246228",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2021-08-06",
    "uploadDate": "2021-12-09T04:59",
    "size": 593753,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT05246228/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [],
  "studyType": "OBSERVATIONAL",
  "enrollmentInfo": {
    "enrollmentCount": 42,
    "enrollmentType": "ESTIMATED"
  },
  "timeline": {
    "startDate": "2022-03-01",
    "completionDate": "2025-12-30",
    "primaryCompletionDate": "2025-11-30",
    "firstSubmitDate": "2021-11-25",
    "firstPostDate": "2022-02-18"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Signed written informed consent.\n* Histologically confirmed diagnosis of cSCC.\n* cSCC categorized as high risk according to ASTRO Guidelines:\n\n  * close or positive margins that cannot be corrected with further surgery (secondary to morbidity or adverse cosmetic outcome).\n  * gross perineural spread, as identified by radiological or pathological assessment.\n  * disease recurrence after a prior margin-negative resection.\n  * pathological stage T3 and T4.\n  * desmoplastic or infiltrative tumors in the setting of chronic immunosuppression at pathological exam, cSCC involving regional lymphnodes, with the exception of a single, small (\\<3 cm) cervical lymph node harboring carcinoma, without extracapsular extension.\n* cSCC addressed to adjuvant radiotherapy as per clinical practice (a complete post-operative treatment should be administered with 50-54 or 60-66 Gy depending on the margin status).\n* Eastern Cooperative Oncology Group (ECOG) Performance status of 0-2.\n\nExclusion Criteria:\n\n* cSCC not eligible for surgery.\n* cSCC not eligible for adjuvant radiotherapy for any condition depending on disease characteristics or patient characteristics, co-morbidities or refusal.\n* Any concurrent investigational product, biologic, or hormonal therapy for cancer treatment.\n* Concurrent treatment with chemotherapy for the purpose of cSCC cure.\n* History or current evidence of any condition that, in the opinion of the treating investigator, might interfere with the subject's participation for the full duration of the trial.\n* Any major surgery, different from that planned for the protocol, in the 15 days before the protocol starting.\n* Any radiotherapy treatment in the 28 days before the protocol starting\n* Pregnant or breastfeeding.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Disease-free survival (DFS) of patients with ALC < 500 cells/mL 28 days after the end of radiotherapy treatment",
        "description": "Disease-free survival (DFS) of patients with ALC \\< 500 cells/mL 28 days after the end of radiotherapy treatment",
        "timeFrame": "28 days after the end of radiotherapy treatment"
      }
    ],
    "secondary": [
      {
        "measure": "Evaluation of changes (Δ) in the circulating immune-cells population before the start of radiotherapy and 28 days after the end of radiotherapy",
        "description": "Evaluation of changes (Δ) in the circulating immune-cells population before the start of radiotherapy and 28 days after the end of radiotherapy.\n\nCorrelation between DFS and circulating immune cell population",
        "timeFrame": "Before and 28 days after the end of radiotherapy treatment"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 1,
      "otherCount": 0,
      "totalCount": 2
    },
    "studyDesign": {
      "phases": [],
      "isRandomized": false,
      "isMasked": true
    },
    "overallComplexityScore": 34,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:30:57.814Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}